Strata Critical Medical, Inc.(SRTA)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,173 of 2,961 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in SRTA
Events flagged as statistical outliers against SRTA's own multi-year baseline — not fixed dollar thresholds.
- Score shock2026-08-04
SRTA quality score dropped 14 points (47→33) on a new filing
View source filing →
SRTA Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Strata Critical Medical, Inc. (SRTA), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores SRTA at 38.9/100 on a 32-signal composite quality model, placing it at rank #2,173 of 2,961 stocks — the bottom half of the AI-ranked universe. SRTA scores in the top quartile across balance sheet strength (91.3), profitability (80.0). Areas of concern include institutional flow (9.9) and free cash flow (13.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 17.4/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Strata Critical Medical, Inc. reports quarterly revenue of $72.5M, net income of $-10.5M, an operating margin of -7.5%. Top institutional holders of SRTA by reported 13-F value include Third Point, Northern Right Capital Management, L.P., BlackRock, based on the most recent SEC filings. SRTA trades on the Nasdaq exchange and files with the SEC under CIK 1779128. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate SRTA daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Strata Critical Medical, Inc. directly from SEC EDGAR. Strata Critical Medical, Inc.'s 13F Pro composite quality score has ranged between 31 and 47 since 2024, currently 38.9 — a stable long-term trajectory across 55 quarterly and live scoring snapshots.
Revenue
Q2 2026
$72.5M
Net Income
Q2 2026
$-10.5M
Free Cash Flow
Q2 2026
$3.2M
Operating Margin
Q2 2026
-7.5%
ROIC
Q2 2026
-7.7%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
+34.3% YoYNet Income
+251.4% YoYOperating Income
+0.8% YoYEPS (Diluted)
+242.9% YoYTotal Assets
+26.8% YoYTotal Debt
Op. Cash Flow
-1841.8% YoYFree Cash Flow
-75.3% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $197.1M +34.3% | $146.8M -34.8% | $225.2M +54.1% | $146.1M | — | — |
| Net Income | $41.3M +251.4% | $-27.3M +51.3% | $-56.1M -105.7% | $-27.3M | — | $-20.5M |
| Operating Income | $-22.4M +0.8% | $-22.5M +66.9% | $-68.1M -27.3% | $-53.5M | — | $-678.5K |
| EPS (Diluted) | $0.50 +242.9% | $-0.35 +53.9% | $-0.76 -100.0% | $-0.38 | — | — |
| Total Assets | $325.5M +26.8% | $256.7M -13.0% | $294.9M -9.3% | $325.0M -3.2% | $335.9M +20.9% | $277.8M |
| Total Debt | — | — | — | $0.00 | — | — |
| Operating Cash Flow | $-48.9M -1841.8% | $-2.5M +92.2% | $-32.3M +12.9% | $-37.1M | — | $-794.5K |
| Free Cash Flow | $-58.5M -75.3% | $-33.4M +3.1% | $-34.5M +9.0% | $-37.9M | — | — |
Get alerted when SRTA's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Strata Critical Medical, Inc. including:
Top Institutional Holders of SRTA
Third Point LLC
$26.4M5,000,000 shNorthern Right Capital Management, L.P.
$25.8M4,890,584 shBlackRock, Inc.
$25.5M4,835,516 shROYCE & ASSOCIATES LP
$16.5M3,132,933 shVANGUARD CAPITAL MANAGEMENT LLC
$15.2M2,885,319 shAWM Investment Company, Inc.
$14.9M2,821,468 shARK Investment Management LLC
$14.4M2,730,855 shFirst Eagle Investment Management, LLC
$12.2M2,314,614 shPillsbury Lake Capital LLC
$11.4M2,171,006 shGEODE CAPITAL MANAGEMENT, LLC
$9.3M1,755,383 sh
| Fund | Value | Shares |
|---|---|---|
| Third Point LLC | $26.4M | 5,000,000 |
| Northern Right Capital Management, L.P. | $25.8M | 4,890,584 |
| BlackRock, Inc. | $25.5M | 4,835,516 |
| ROYCE & ASSOCIATES LP | $16.5M | 3,132,933 |
| VANGUARD CAPITAL MANAGEMENT LLC | $15.2M | 2,885,319 |
| AWM Investment Company, Inc. | $14.9M | 2,821,468 |
| ARK Investment Management LLC | $14.4M | 2,730,855 |
| First Eagle Investment Management, LLC | $12.2M | 2,314,614 |
| Pillsbury Lake Capital LLC | $11.4M | 2,171,006 |
| GEODE CAPITAL MANAGEMENT, LLC | $9.3M | 1,755,383 |
Companies Similar to SRTA
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
BIOLIFE SOLUTIONS INC
SANUWAVE Health, Inc.
MeiraGTx Holdings plc
Apellis Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc.
KYNTRA BIO, INC.
CareDx, Inc.
Arcutis Biotherapeutics, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put SRTA on your watchlist
Track score changes the day Strata Critical Medical, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is SRTA a good stock to buy?
13F Pro's AI-powered analysis of Strata Critical Medical, Inc. (SRTA) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for SRTA are available on the SRTA stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. SRTA is classified as a small company.
Which hedge funds own SRTA?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling SRTA. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Strata Critical Medical, Inc.'s investment landscape.